89102-76-1

Upstream product

• 14731-10-3 3-(chloromethyl)-5-phenylisoxazole 
• 1067-71-6 Diethyl (2-oxopropyl)phosphonate 
• 93-89-0 benzoic acid ethyl ester 
• 1273328-91-8 diethyl 4-hydroxy-2-oxo-4-phenylbut-3-enylphosphonate 
• 122-52-1 triethyl phosphite 
• 110841-50-4 N-<2-(diethoxyphosphoryl)ethylidene>hydroxylamine 
• 1606-75-3 (2-oxoethyl)phosphonic acid diethyl ester 
• 107486-98-6 N-<1-chloro-2-(diethoxyphosphoryl)ethylidene>hydroxylamine 
• 536-74-3 phenylacetylene 

Downstream Products

• 145432-90-2 [[1,3]Dithiepan-2-ylidene-(5-phenyl-isoxazol-3-yl)-methyl]-phosphonic acid diethyl ester 
• 145432-92-4 [[1,3]Dioxolan-2-ylidene-(5-phenyl-isoxazol-3-yl)-methyl]-phosphonic acid diethyl ester 
• 145432-88-8 [[1,3]Dithian-2-ylidene-(5-phenyl-isoxazol-3-yl)-methyl]-phosphonic acid diethyl ester 
• 145432-86-6 [[1,3]Dithiolan-2-ylidene-(5-phenyl-isoxazol-3-yl)-methyl]-phosphonic acid diethyl ester 

Relevant academic research and scientific papers

HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS

This invention relates to compounds of formula (I) and their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurolog

HETEROCYCLIC MGLU5 ANTAGONISTS

Compounds (I) (R1 is an optionally substituted C1-C13 heteromonocyclic, heterobicyclic or heterotri cyclic group containing from 1 to 5 heteroatoms selected from N, O and S; R2 is H, an optionally substituted mo

Antibacterial monic acid derivatives

A compound of the formula (I) STR1 wherein R is a group STR2 R1 is hydrogen, phenyl, C1-20 alkyl, C2-8 alkenyl or C2-8 alkynyl each of which may optionally be substituted; or C3-7 cycloalkyl, X is a divalent group --Y--C=C--, and Y is oxygen or sulphur, have antibacterial and/or antimycoplasmal activity.